Recombinant RSV (Palivizumab Biosimilar) anticorps

N° du produit ABIN7795088

Cet anticorps Humanized Monoclonal détecte spécifiquement RSV (Palivizumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant RSV (Palivizumab Biosimilar) anticorps (ABIN7795088)

Antigène: RSV (Palivizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp RSV (Palivizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-RSV (Palivizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Palivizumab Biosimilar, Endotoxin 0.05 EU/mg

Attributs du produit: Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: Less than 0.5 EU/mg of protein as determined by LAL method

Immunogène: Respiratory Syncytial Virus F protein

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur RSV (Palivizumab Biosimilar)

Antigène: RSV (Palivizumab Biosimilar)

Autre désignation: Palivizumab Biosimilar

Classe de substances: Biosimilar